Eli Lilly touts skyrocketing Mounjaro prescriptions even as it reports an overall slump in 2022 revenue
Eli Lilly is betting big on its type 2 diabetes drug Mounjaro amid skyrocketing prescriptions since its launch.
The company expects US net prices to continue to increase as access is broadened and paid prescriptions for the drug also increase.
Prescriptions for Mounjaro peaked at about 180,000 per week in December, far outpacing its own established type 2 drug Trulicity, according to Lilly data reported in its earnings report on Thursday. While Mounjaro only brought in Q4 revenue of $279.2 million, it’s expected to quickly become a blockbuster.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.